论文部分内容阅读
目的在回顾性分析99例非小细胞肺癌骨转移病例临床特征。方法番禺区中心医院肿瘤科2004年7月～2008年7月收治的所有非小细胞肺癌骨转移病例。结果符合条件的临床病例共99例,中位生存时间8.3月(1.4月～38.5月)。43例(43.4%)发生骨相关事件。化疗后发生骨转移的患者更常见发生骨相关事件(P=0.020),使用唑来膦酸可能减少骨相关事件的发生(P=0.075)。单因素分析显示,PS状态(P=0.049)、是否发生骨相关事件(P=0.001)影响生存。Cox回归多因素分析显示,影响非小细胞肺癌骨转移患者预后的独立因素为是否合并肝转移(P=0.044)、是否发生骨相关事件(P=0.000)。既往曾行肺原发灶放疗患者预后可能较好(P=0.085)。结论早期发现、早期诊断骨转移并使用唑来膦酸可能可以减少非小细胞肺癌骨相关事件的发生并改善预后。
Objective To retrospectively analyze the clinical features of 99 cases of non-small cell lung cancer with bone metastases. Methods Panyu Central Hospital Department of Oncology July 2004 ~ July 2008 admitted to all cases of non-small cell lung cancer bone metastases. Results A total of 99 clinical cases were eligible. The median survival time was 8.3 months (1.4 to 38.5 months). Bone-related events occurred in 43 cases (43.4%). Bone-related events were more common in patients with bone metastases after chemotherapy (P = 0.020), and zoledronic acid use may reduce the incidence of bone-related events (P = 0.075). Univariate analysis showed that PS status (P = 0.049), presence of bone-related events (P = 0.001) affected survival. Cox regression multivariate analysis showed that independent factors affecting the prognosis of non-small cell lung cancer patients with bone metastases were liver metastases (P = 0.044) and bone-related events (P = 0.000). Previously performed primary lung cancer patients with radiotherapy prognosis may be better (P = 0.085). Conclusion Early detection of early diagnosis of bone metastases and the use of zoledronic acid may reduce the incidence of non-small cell lung cancer bone-related events and improve prognosis.